Topic summary

Reading SURMOUNT-1 without the press release — one year on

Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed

This is a generated summary. It shows the 7 most-liked posts from a topic of 51, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

o.abrahamsenTL3Regular23 Aug 2025#4

c.correia, post #1: Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1 without the press, and I would like to be argued out of it if the disagreement is bad. The disagreement is about one step, not… Go to post

Bookmarking this. I will come back when I have something worth adding.

32 likes in reply to #1 11mo

c.inglethorpeTL3Regular Solution14 Sep 2025#8

Building on post #7 rather than restating it.

I would rather this thread reach "we do not know" about Reading SURMOUNT-1 without the press than reach a confident answer that nobody can support when asked.

24 likes 10mo

d.achebeTL221 Oct 2025#16

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

25 likes 9mo

lyophil_marginTL3Regular1 Dec 2025#26

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

29 likes 8mo

coldchain_liuTL3Regular30 Dec 2025#34

SURMOUNT-4's randomised withdrawal design is the strongest available evidence about what happens on stopping. It says nothing about a lower maintenance dose, because the comparison was continue versus placebo rather than continue versus less.

31 likes 7mo

n.achebeTL210 Feb 2026#46

Confirming post #45 from a second method, which matters more than confirming it from a second person.

Offering a way to settle Reading SURMOUNT-1 without the press rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.

32 likes 6mo

dexa_twice_yearlyTL3Regular27 Feb 2026 · edited#51

Confirming post #48 from a second method, which matters more than confirming it from a second person.

Small methodological point on Reading SURMOUNT-1 without the press: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.

26 likes 5mo

Read the full topic (51 posts)

This topic was referenced in

What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long versionCompounds › Tirzepatide · 52 replies
[2026 update] Does dual agonism explain the effect size, or is it dose?Compounds › Tirzepatide · 63 replies

This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
SURPASS-2 and the comparator dose question that will not go away — what changed since Compounds › Tirzepatide SURMOUNT programme tirzepatide effect size Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. What changes if the standard…	+2	6	5.5k	7h
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…	+15	19	930	18mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…	+7	11	281	6mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide tirzepatide SURMOUNT programme effect size randomised trial Solved Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…	+109	122	3.6k	2mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Posting a small dataset on 2.5…	+12	16	11k	7mo

Related topics — sharing the tags effect size, SURPASS programme, randomised trial

Topic	Participants	Replies	Views	Activity
Coming back to: A critique that turned out to be unfair, retracted by its author Evidence › Study critique disputed observational data effect size confounding Closed A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about critique, three…		2	1.3k	14mo
A critique that turned out to be unfair, retracted by its author Evidence › Study critique confounding risk of bias effect size observational data Wiki Posting this under the heading it deserves: A critique that turned out to be unfair, retracted by its author Everything below is what sits behind that. Critique, and specifically the version of it that the…	+34	38	20k	17h
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Retatrutide phase 2 in type that I did…	+1	5	31k	8mo
Prediction intervals and why they are more honest than confidence intervals Evidence › Meta-analyses heterogeneity risk of bias effect size publication bias Solved Closed Posting this under the heading it deserves: Prediction intervals and why they are more honest than confidence intervals Everything below is what sits behind that. I have spent a fortnight trying to pin…	+21	25	46k	4mo